Introduction
Venous thromboembolism (VTE) is a severe clinical condition occurring either as deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Venous thromboembolism is one of the most common cardiovascular diseases following myocardial infarction and stroke. 1 In developed countries, the incidence of venous thromboembolism is between 1 and 2 per 1,000 persons per year 2, 3 and pulmonary embolism still remains an important issue with a high mortality rate. 4 About two-thirds of deep venous thrombosis episodes occur in conjunction with external factors, such as surgery, immobilization or trauma. 5 For women there are further risk factors, namely pregnancy, puerperium and oral contraceptive use (OC). Also, there are demographic and conditional risk factors for initial venous thromboembolism: advanced age, 6 ,7 obesity 8 and cancer. Data on survival after venous thromboembolism are scarce and vary considerably. Reports on short-term survival vary from 95% to 97% following deep venous thrombosis 9,2 and from 77% to 94% following pulmonary embolism. 2, 7, 10 Longterm survival rates for both deep venous thrombosis and pulmonary embolism range from 61% to 75%. 2, 7, 8, 11, 12 The aim of our study was to evaluate the long-term survival among women with venous thromboembolism at a relatively young age and to compare their survival to the general population.
Design and Methods
All women aged 13 to 45 with a history of venous thromboembolism who visited our outpatient clinic for routine coagulation screening between January 1985 and December 1998 and who had no malignancy at first presentation were included. The event had always been documented by objective methods, such as phlebography, plethysmography, duplex ultrasonography, perfusion ventilation lung scan or computed tomography. Short-term oral anticoagulation with vitamin K antagonists after the first deep venous thrombosis or pulmonary embolism was defined as up to six months; longterm anticoagulation was usually only recommended in patients with lupus anticoagulant, antithrombin deficiency or combined genetic defects.
A retrospective survival analysis of the above-mentioned patients for the period 1 st January 1985 to 31 st December 2006 was performed. The observation period started when the patient was first seen at our department (median 1.57 years following their first episode of VTE; IQR 0.41-8.7 years). In addition to patient file information, data on mortality was obtained from the Austrian Central Death Register, which is maintained by Statistics Austria. Causes of death were Long-term survival after venous thromboembolism: a retrospective selected cohort study among young women ABSTRACT coded according to the International Classification of Diseases (ICD). Overall mortality of the general Austrian female population was also obtained from Statistics Austria. The survival of our patients was estimated and summarized using the Kaplan-Meier method. 13 After adjustment for age and calendar period, the patient mortality rates were compared with those of the general Austrian female population using relative survival methods.
14 Calculations were made in SAS and SAS macros provided by Dickman et al. 15 Differences between groups were analyzed using the Fisher's exact test and the JonckheereTerpstra test for testing an ordered alternative.
Results and Discussion
Our study includes 728 women with a median age of 28.7 years (interquartile range (IQR) 21.6-36.3 years) at manifestation of venous thromboembolism. Patients' characteristics are listed in Table 1 . In 400 patients (55%), venous thromboembolism was secondary, i.e. following a triggering event. The median follow-up time, i.e. visit at our clinic for routine coagulation screening until December 2006 or death, respectively, was 14 years. Sixty-one percent of our patients received short-term oral anticoagulation with vitamin K antagonists after the first deep venous thrombosis or pulmonary embolism, a further 18% used oral contraceptives for 6-18 months and 18% had long-term anticoagulation. For 3% of the patients, data on the duration of oral contraceptives are not available.
During the entire analysis period of 22 years, a total of 23 patients (3.2%) died. Causes of death were cancer in 6 patients (26%), bleeding and thrombosis each in 2 (8.7%), heart disease in 4 (17.4%), and stroke in one patient (4.3%). Six patients (26%) died due to various other causes and for 2 patients (8.7%) the cause of death is not clearly defined due to vague coding in the ICD. The mean age at death was 57 years (IQR 52-70 years). The mean age of the surviving women was 48 years (IQR 40-57 years). Of those with short-term anticoagulation 13 patients (2.9%), of those with anticoagulation between 6-18 months one patient (0.8%), and of those with long-term anticoagulation 7 patients (5.5%) died. Statistical analysis of the different groups of oral contraceptive users did not show a significant difference with a P value of 0.0828 when using the Fisher's exact test and a P value of 0.536 when using the Jonckheere-Terpstra test. 16 The cumulative relative survival of our patients in comparison to the general Austrian female population was 1.03 (95% confidence interval 0.99-1.04; Figure 1 ). Neither the subgroup of women with pulmonary embolism (cumulative relative survival 1.03, 95% CI 1.01-1.04) nor those with spontaneous (without a known triggering event) events (1.03, 95% CI 0.99-1.06) had a decreased survival in comparison to the general population. Our data show that long-term survival of young women with a history of venous thromboembolism does not differ from the survival of the general Austrian female population.
There are only few data on the long-term survival rate in patients following venous thromboembolism available. Schulman et al. 7 reported on a 10-year death rate of 28.5%. This high mortality rate may be due to patients' characteristics, specifically the higher age at first venous thromboembolism (more than 50% over 60 years) and co-morbidities, such as cancer or cardiovascular diseases. A comparison to the general population or a population with similar co-morbidities was not performed.
Heit et al. 17 reported an 8-year survival rate of 47.5% following venous thromboembolism. Patients from this cohort had a reduced survival in comparison to the residents of Minnesota due to a higher mortality in the first months. Interestingly, although patients with deep venous thrombosis and/or pulmonary embolism had a decreased survival in the first months after thrombosis, the survival curve of the patient cohort is parallel to the expected survival of Minnesota residents after approximately one year. Further important differences to our study are the presence of malignancies in the patient cohort and their higher age.
Naess et al. 1 estimated the mortality after venous thromboembolism for the population of Nord-Trondelag and found a one year case fatality rate of 21.6% (12.6% in patients without cancer). They noted the highest risk of death during the first few months following venous thromboembolism; thereafter, the mortality rate in noncancer patients gradually reached that of the general population. These results on long-term survival are comparable to our findings.
Recent data from the MEGA-study in the Netherlands 18 show a 2-fold increased risk of death in patients without a malignancy following an episode of venous thromboembolism compared to the general population. Again, this study includes all patients under 70 years of age, which might also explain the differences to our findings. Optimal duration of anticoagulation in patients with venous thromboembolism is still being discussed. Contrary to previous versions, in 2008 the American College of Chest Physicians (ACCP) recommended (grade 1A) long-term anticoagulation in those with a single episode of proximal deep venous thrombosis or pulmonary embolism, when no transient risk factors are present. 19 These guidelines are based on interventional studies [20] [21] [22] [23] in patients, who had discontinued anticoagulation. Death rates given in these studies (below 6%) did not differ among patients with and without anticoagulation except for the study by Schulman et al. 23 who reported a higher death rate in patients with recurrent venous thromboembolism in whom warfarin had been stopped.
Our study shows no significant difference regarding survival considering different duration periods of oral contraceptive use. The largest proportion of patients died in the group with long-term anticoagulation. This might be due to their risk profile which, most probably, was actually the reason for the initial long-term anticoagulation.
Our study has several limitations. The most important one is the retrospective design. However, we included all women with venous thromboembolism who visited our department during a given time period, which can be seen as a strength of this study. The Austrian Death Register covers all deaths occurring within Austria. Since the tendency to relocate in Austria is rather low, we are sure we have covered the vast majority of deaths. Moreover, our study shows a tendency towards better survival, so even if we had missed a small number of deaths the results would not change. However, in the majority of our patients a triggering event could be identified, which correlates to a lower risk profile. This might also explain the tendency for a better survival in our patient cohort. Another limitation is that our study does not cover the acute phase following venous thromboembolism; therefore, we are unable to draw any conclusions concerning short-term survival. However, this was actually not the aim of our study. Our data also cannot be applied to men or older patients; these groups have to be investigated separately. With regard to risk factors for venous thromboembolism, there might be some recall bias as patients were referred to our department some time after initial occurrence of venous thromboembolism.
In conclusion, our results show that in the long term, after the more critical initial period, venous thromboembolism does not influence survival of young women. Anticoagulation considerably influences the quality of life, and young women of childbearing age may fear the wellknown embryotoxic effect. When deciding on treatment modalities, particularly long-term anticoagulation, the risk of fatal bleeding and other untoward effects should always be assessed versus the risk of fatal recurrent venous thromboembolism 24 which, according to our data, seems to be very low in young women.
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